News und Analysen

CRISPR Therapeutics (NASDAQ: CRSP) may be a few months away from a transformation. The company itself isn't changing, but its financial picture may be about to do so. That's because by year-end

CRISPR Therapeutics (NASDAQ: CRSP) may be a few months away from a transformation. The company itself isn't changing, but its financial picture may be about to do so. That's because by year-end

CRISPR Therapeutics (NASDAQ: CRSP) may be a few months away from a transformation. The company itself isn't changing, but its financial picture may be about to do so. That's because by year-end

Image source: The Motley Fool.

Abbott Laboratories (NYSE: ABT)Q2 2023 Earnings CallJul 20, 2023, 9:30 a.m. ET

Operator

Continue reading

Source Fool.com

Over the past three years, Novavax (NASDAQ: NVAX) has lost an astonishing 92% of its value on the market. The reason for that is no secret. The biotech quickly established itself in the race to

There's no healthcare company that's worth anywhere near $1 trillion today. But within the next 10 years, that's likely to change, given the many growth opportunities emerging in the industry. Two

There's no healthcare company that's worth anywhere near $1 trillion today. But within the next 10 years, that's likely to change, given the many growth opportunities emerging in the industry. Two

A high-yielding dividend stock can generate lots of dividend income for your portfolio. But that doesn't mean you should buy a stock only because of its yield. Dividends are never guaranteed and

A high-yielding dividend stock can generate lots of dividend income for your portfolio. But that doesn't mean you should buy a stock only because of its yield. Dividends are never guaranteed and

Shares of Novavax (NASDAQ: NVAX) have been jumping in the past month, and they are up around 25% since April. There's an influx of money coming its way due to unused COVID shots in Canada, which

After a down 2022, growth stocks are making a big comeback this year. The S&P 500 Growth index is up more than 21% this year, while the S&P 500 Value index is up just a little more than 13%

After a down 2022, growth stocks are making a big comeback this year. The S&P 500 Growth index is up more than 21% this year, while the S&P 500 Value index is up just a little more than 13%

After a down 2022, growth stocks are making a big comeback this year. The S&P 500 Growth index is up more than 21% this year, while the S&P 500 Value index is up just a little more than 13%

You need money to make money with stocks. While there's no minimum you have to invest, $5,000 is a good figure I strive for as a minimum. It means you've got some decent skin in the game where

You need money to make money with stocks. While there's no minimum you have to invest, $5,000 is a good figure I strive for as a minimum. It means you've got some decent skin in the game where

Pfizer (NYSE: PFE) and Viatris (NASDAQ: VTRS) have a common past. That's because Viatris came about a few years ago when Pfizer's Upjohn business merged with generic drug giant, Mylan. Since, their

Pfizer (NYSE: PFE) and Viatris (NASDAQ: VTRS) have a common past. That's because Viatris came about a few years ago when Pfizer's Upjohn business merged with generic drug giant, Mylan. Since, their

Shares of ImmunityBio (NASDAQ: IBRX) were up 10% at 11:40 a.m. ET on Wednesday. The clinical-stage biotech company focuses on cell therapies and immunotherapy platforms, including vaccines and

Shares of Amarin (NASDAQ: AMRN) were sinking 22.7% as of 10:56 a.m. ET on Wednesday. The steep decline came after the drugmaker announced an organizational restructuring after the market close on

Over the past few years, Biogen (NASDAQ: BIIB) has been engaged in a much-talked-about journey to develop an effective Alzheimer's disease (AD) medicine. On July 6, the company announced that along

Over the past few years, Biogen (NASDAQ: BIIB) has been engaged in a much-talked-about journey to develop an effective Alzheimer's disease (AD) medicine. On July 6, the company announced that along

Over the past few years, Biogen (NASDAQ: BIIB) has been engaged in a much-talked-about journey to develop an effective Alzheimer's disease (AD) medicine. On July 6, the company announced that along

The healthcare sector is unlikely to become obsolete anytime soon, but individual companies can very much get left behind if they fail to keep up with the changing dynamics of the industry. That's

The healthcare sector is unlikely to become obsolete anytime soon, but individual companies can very much get left behind if they fail to keep up with the changing dynamics of the industry. That's